Xospata
Total Payments
$5.7M
Transactions
10,254
Doctors
4,114
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.6M | 4,361 | 2,366 |
| 2023 | $2.3M | 3,833 | 2,245 |
| 2022 | $1.7M | 2,029 | 1,080 |
| 2021 | $44,609 | 15 | 13 |
| 2020 | $9,600 | 7 | 7 |
| 2019 | $27,951 | 9 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 1,117 | 80.5% |
| Consulting Fee | $402,565 | 134 | 7.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $239,631 | 76 | 4.2% |
| Food and Beverage | $210,176 | 8,657 | 3.7% |
| Travel and Lodging | $115,377 | 153 | 2.0% |
| Grant | $67,125 | 23 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $65,689 | 25 | 1.2% |
| Honoraria | $2,000 | 1 | 0.0% |
| Education | $1,114 | 68 | 0.0% |
Payments by Type
Research
$4.6M
1,117 transactions
General
$1.1M
9,137 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | Astellas Pharma Global Development | $1.7M | 0 |
| A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with an Activating FLT3 Mutation | Astellas Pharma Global Development | $713,031 | 0 |
| Randomized Trial of Gilteritinib vs Midostaurin in FL T3 Mutated Acute Myeloid Leukemia | Astellas Pharma Global Development | $553,381 | 0 |
| This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. | Astellas Pharma Global Development | $374,569 | 0 |
| A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia | Astellas Pharma Global Development | $289,552 | 0 |
| A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Astellas Pharma Global Development | $185,180 | 0 |
| Effect of gilteritinib treatment on allogeneic NK cell-mediated cytotoxicity in FLT3-ITD mutant acute myeloid leukemia | Astellas Pharma Global Development | $147,000 | 0 |
| A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy | Astellas Pharma Global Development | $144,011 | 0 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $133,644 | 9 |
| This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients | Astellas Pharma Global Development | $103,446 | 0 |
| A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function | Astellas Pharma Global Development | $41,154 | 0 |
| Phase Ib trial of gilteritinib in combination with mitoxantrone, cladribine, cytarabine and filgrastim (GM-CLAG) for relapsed/refractory FLT3-mutated acute myeloid leukemia | Astellas Pharma Global Development | $33,000 | 0 |
| Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) | Astellas Pharma Global Development | $32,016 | 0 |
| This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequenc | Astellas Pharma Global Development | $28,394 | 0 |
| A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3ITD AML | Astellas Pharma Global Development | $27,048 | 0 |
| A non interventional cohort study of the CLonal EVOlution of FLT3 mutations during disease progression in patients with acute myeloid leukemia CLEVO | Astellas Pharma Europe BV | $11,865 | 0 |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | Astellas Pharma Global Development | $10,265 | 0 |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | Astellas Pharma Global Development | $9,350 | 0 |
| A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well | Astellas Pharma Inc | $8,602 | 0 |
| A Retrospective Cohort Study of the Persistence of FLT3- Tyrosine Kinase Inhibitor Therapy in Acute Myeloid Leukemia Patients | Astellas Pharma Global Development | $6,902 | 1 |
Top Doctors Receiving Payments for Xospata
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Morgantown, WV | $4.6M | 1,045 |
| George Yaghmour | Hematology & Oncology | Los Angeles, CA | $114,358 | 79 |
| , M.D | Internal Medicine | Baltimore, MD | $79,728 | 38 |
| , MD | Hematology & Oncology | New York, NY | $54,768 | 50 |
| , M.D | Hematology | Hackensack, NJ | $40,620 | 36 |
| , M.D., PH.D | Hematology | Hawthorne, NY | $33,757 | 31 |
| , MD | Internal Medicine | Hershey, PA | $27,551 | 10 |
| , M.D | Hematology | Duarte, CA | $25,000 | 1 |
| , MBBS | Hematology & Oncology | Houston, TX | $24,900 | 24 |
| , MD | Hematology & Oncology | Chica, IL | $21,105 | 24 |
| , M.D | Internal Medicine | Stanford, CA | $20,696 | 16 |
| , MD, MA | Medical Oncology | Durham, NC | $20,073 | 19 |
| , M.D., PHD | Student in an Organized Health Care Education/Training Program | Orlando, FL | $18,831 | 11 |
| , M.D., M.P.H | Hematology & Oncology | Washington, DC | $17,911 | 11 |
| , M.D | Internal Medicine | San Francisco, CA | $16,740 | 14 |
| , MD | Medical Oncology | Philadelphia, PA | $16,105 | 28 |
| , MD | Internal Medicine | Charlotte, NC | $14,588 | 8 |
| , MD | Hematology | Buffalo, NY | $13,477 | 23 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $13,306 | 7 |
| , M.D | Hematology & Oncology | Boston, MA | $12,753 | 8 |
| , MD | Internal Medicine | Durham, NC | $9,534 | 4 |
| , MD | Internal Medicine | Dallas, TX | $9,501 | 8 |
| , MD, PHD | Hematology & Oncology | Portland, OR | $9,490 | 9 |
| , MD | Internal Medicine | Stanford, CA | $9,300 | 3 |
| , MD | Hematology & Oncology | San Diego, CA | $8,953 | 12 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $4.7M
- Astellas Pharma US Inc $816,390
- Astellas Pharma Inc $83,033
- Astellas Pharma Europe Ltd $40,875
- Astellas Pharma Europe BV $11,865
- Astellas US LLC $106.67
Product Information
- Type Drug
- Total Payments $5.7M
- Total Doctors 4,114
- Transactions 10,254
About Xospata
Xospata is a drug associated with $5.7M in payments to 4,114 healthcare providers, recorded across 10,254 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2019 to 2024. In 2024, $1.6M was paid across 4,361 transactions to 2,366 doctors.
The most common payment nature for Xospata is "Unspecified" ($4.6M, 80.5% of total).
Xospata is associated with 20 research studies, including "A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy" ($1.7M).